Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The Unpublished Phase I Trial The most significant human trial, NCT02637284, was a Phase I safety and pharmacokinetics study conducted in 2015 with healthy volunteers
Customizing dosing, strengths, and delivery forms to match patient-specific needs under prescriber guidance
Stacking and Combinations GHK Cu stacks well with several peptides and wellness approaches
Progressive Fat Loss Phase (Weeks 4-12): The most significant body composition improvements typically occur between weeks four and twelve of consistent AOD-9604 use
PMID 17766407
US$ 25.86
US$ 26.83
US$ 28.35
